<DOC>
	<DOCNO>NCT01664104</DOCNO>
	<brief_summary>This observational , multi-center study evaluate treatment regimen , treatment response safety RoActemra/Actemra ( tocilizumab ) therapy routine clinical practice patient moderate severe rheumatoid arthritis . Data collect 6 month .</brief_summary>
	<brief_title>An Observational Study Evaluate RoActemra/Actemra ( Tocilizumab ) Treatment Real-Life Setting</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Diagnosis moderate severe rheumatoid arthritis Patients start RoActemra/Actemra treatment accord routine clinical practice within 3 month prior study start Patients give oral write information study sign informed consent form Patients start RoActemra/Actemra treatment 3 month prior site opening Patients previously receive RoActemra/Actemra clinical trial set compassionate use Patients enrol ongoing clinical trial and/or receive treatment investigational drug within 4 week prior study start Patients history autoimmune disease joint inflammatory disease rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>